Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver
Chronic Hepatitis C Infection, Fatty Liver
About this trial
This is an interventional treatment trial for Chronic Hepatitis C Infection focused on measuring Genotype 1, Metabolic syndrome, Insulin resistance
Eligibility Criteria
Inclusion Criteria: Men and women at least 21 years of age. Positive serum hepatitis C RNA for at least 6 months. Naive to any therapy for hepatitis C infection. Significant steatosis or fat on the liver biopsy. Genotype 1 patients. Exclusion Criteria: Subjects with decompensated liver disease. Hemoglobin <12g/dl. WBC<2,000mm3. ANC<1,000mm3. Platelet count<50,000/mm3. Creatinine>1.5mg/dl. Albumin<2.5g/dl. Bilirubin>4mg/dl. HIV or hepatitis B co-infection. History of other liver disease besides fatty liver disease. History of unstable cardiac or cerebrovascular disease. History of significant psychiatric disorders. Alcohol or drug abuse within last year. Pregnant or lactating women or men whose sexual partner is pregnant or lactating. Taking of insulin or oral hypoglycemic agents within six months of the study. Uncontrolled thyroid disorder. History of malignancy within the past 5 years unless cured by surgery. History of autoimmune disorder or organ transplantations requiring immunosuppression.
Sites / Locations
- Beth Israel Medical Center - Philipps Ambulatory Care Center